Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 29 |
| Active Pipeline (Recruiting Now) | 9 (6) |
| Completed vs Stopped Early | 15 / 5 (17.2%) |
| Median Closed Actual Enrollment | 185 participants |
| Physical Hospital Site Disclosure | 99.9% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 8 (3 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Fukushima Medical University Hospital | Fukushima | 6 |
| Emory Winship Cancer Institute | Atlanta, GA | 5 |
| Johns Hopkins Hospital and Kimmel Cancer Center | Baltimore, MD | 5 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07123155 | Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD) | Phase II | RECRUITING |
| NCT07214571 | A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Seve | Phase II | RECRUITING |
| NCT04110054 | Evaluation of S-600918 in Adults With Refractory Chronic Cough | Phase II | COMPLETED |
| NCT04569084 | Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS | Phase III | TERMINATED |
| NCT05151471 | Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS | Phase III | TERMINATED |
Explore interactive annual charts and M&A subsidiary rollups in the Shionogi Interactive Dossier, benchmark peers in Infectious Disease and Vaccines, or review the Healthcare Price & Patent Cliff Crosswalk.